CreamerD, WalshSA, DziewulskiP, et al.U.K. guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. Br J Dermatol, 2016; 174:1194–1227.
2.
HeymannWR.More than Mycoplasma-induced rash and mucositis: the potential role of Mycoplasma pneumoniae in Stevens-Johnson syndrome/toxic epidermal necrolysis. J Am Acad Dermatol, 2022; 86:746–747.
3.
KridinK, BrüggenMC, ChuaSL, et al.Assessment of treatment approaches and outcomes in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: insights from a pan-European multicenter study. JAMA Dermatol, 2021; 157:1182–1190.
4.
JacobsenA, OlabiB, LangleyA, et al.Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome. Cochrane Database Syst Rev, 2022; 3:CD013130.
5.
Bastuji-GarinS, FouchardN, BertocchiM, et al.SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol, 2000; 115:149–153.
